Pharmaceutical and Biotech

The new patient experience enables Life Sciences companies to create competitive advantage and deliver superior personalized, patient and physician-centric experiences.

It is a holistic approach to “harmonize product, nature and life,” and deliver new therapies that encompass human data including genomics, behavior and the environment and leverages technology advancements in modeling, simulation and IoT such as wearables, smart objects and more, to achieve personalized, predictive, preventive, and participatory therapies.

Capitalizing on the technologies available to deliver new therapies will drive transformation, create competitive advantage and significantly improve the patient experience.

As Life Sciences companies strive for superior patient experiences there will be a need to better manage global changes, global market registration, and total quality processes. Improved regulatory intelligence, along with enhanced therapeutics ”in-silico” design, a shift toward biologics, and outcomes-based health economics can help accelerate the best products to market, reducing the overall Life Sciences industry attrition rate.

The goal is to create an integrated framework for compliant innovation, embed quality and regulatory best practices early in the development process, and to provide end-to-end product traceability throughout the lifecycle of the product. This process allows for higher quality, compliant products and faster regulatory approvals.

Pharmaceutical and Biotech companies are under significant pressure to lower costs and to deliver therapies to smaller populations. Leading companies are investing in more flexible infrastructure, leveraging disposable and modular equipment in order to be more adaptive, mainly driven by the acceleration of biologics. The need for continuous scale-up and efficient tech-transfer will become mandatory and the use of best practices in mobile, flexible, disposable and additive will drive toward more agile manufacturing and planning operations to provide the agility of serving more people around the world.

Redefined value network (CROs, CMOs, Suppliers), marketplace for health, service supplemented experiences, embrace consumerization of health.

As Life Science companies look to leapfrog their competition by accelerating innovation, maximizing ROI and creating new, connected patient experiences, we will see a significant growth in collaborative invention and new models will emerge throughout manufacturing and value chain.

Services supplemented experiences will provide for more intelligent, efficient and collaborative open innovation and Life Sciences companies will drive toward more personalized experiences, embracing the consumerization of health.